Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

NCT03793166 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03793166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03793166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 7, 2019
Completion date
January 25, 2028
Enrollment
1,175 (estimated)
Sites
859

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, metastatic malignant neoplasm in the bone, metastatic malignant neoplasm in the lymph nodes, metastatic malignant neoplasm in the soft tissue, metastatic malignant neoplasm in the viscera, rhabdoid tumor of the kidney, sarcomatoid renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8